Enzyvant, which focuses on developing regenerative medicines for rare diseases, has laid out plans to build a new manufacturing facility in the Research Triangle Park area of North Carolina.
Construction of the 25,972 square-foot plant is set to begin this summer and be complete by mid 2025. The company, a subsidiary of Sumitomo Pharma, already has an R&D facility nearby in Durham, North Carolina.
The financial terms of the project weren’t disclosed.
The company plans to primarily focus on making Rethymic, used to treat pediatric patients with congenital athymia, a rare immune disorder, at the site. Rethymic is the first thymus tissue product approved by the FDA.
In addition, the company is "looking ahead to potential needs in other indications and in support of other advanced regenerative medicine technologies,” William Symonds, Enzyvant's chief executive, said in a statement. “This new facility, once completed, will give us the size, flexibility, and nimble processing capability to serve both commercial and research needs.”
Just under a year ago, Enzyvant sold off its preclinical Farber disease therapy RVT-801 to Aceragen for $35 million. The company had been looking since the onset of the COVID-19 pandemic to offload the novel treatment designed to combat the accumulation of ceramide in patients with Farber, a lysosomal storage disease.